MA39524A1 - 1h-1,8-naphthyridin-2 ones utilisées comme composés anti prolifératifs - Google Patents

1h-1,8-naphthyridin-2 ones utilisées comme composés anti prolifératifs

Info

Publication number
MA39524A1
MA39524A1 MA39524A MA39524A MA39524A1 MA 39524 A1 MA39524 A1 MA 39524A1 MA 39524 A MA39524 A MA 39524A MA 39524 A MA39524 A MA 39524A MA 39524 A1 MA39524 A1 MA 39524A1
Authority
MA
Morocco
Prior art keywords
naphthyridin
ones used
antiproliferative compounds
compounds
ones
Prior art date
Application number
MA39524A
Other languages
English (en)
Inventor
Amala Kompella
Venugopala Krishna Gampa
Srinivasulu Ganganamoni
Balakrishna Reddy Sirigireddy
Kali Satya Bhujanga Rao Adibhatla
Venkaiah Chowdary Nannapaneni
Original Assignee
Natco Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52589723&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA39524(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Natco Pharma Ltd filed Critical Natco Pharma Ltd
Publication of MA39524A1 publication Critical patent/MA39524A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne de nouvelles 1h-1,8-naphthyridin-2-ones antiprolifératives de formule générale (i) ou des sels pharmaceutiquement acceptables de celles-ci, dans lesquelles les groupes variables sont tels que définis dans la description, et leur préparation et leur utilisation dans le traitement thérapeutique de troubles liés à l'inhibition de tyrosine kinases chez les animaux à sang chaud. Ces composés peuvent surmonter la résistance aux médicaments induite par l'imatinib.
MA39524A 2014-06-06 2016-12-05 1h-1,8-naphthyridin-2 ones utilisées comme composés anti prolifératifs MA39524A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2781CH2014 2014-06-06
PCT/IN2014/000777 WO2015186137A1 (fr) 2014-06-06 2014-12-15 1h-1,8-naphthyridin-2 ones utilisées comme composés anti prolifératifs

Publications (1)

Publication Number Publication Date
MA39524A1 true MA39524A1 (fr) 2018-01-31

Family

ID=52589723

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39524A MA39524A1 (fr) 2014-06-06 2016-12-05 1h-1,8-naphthyridin-2 ones utilisées comme composés anti prolifératifs

Country Status (18)

Country Link
US (2) US9765072B2 (fr)
EP (1) EP3152205A1 (fr)
JP (1) JP2017516867A (fr)
KR (1) KR20170016921A (fr)
CN (1) CN106573929A (fr)
AP (1) AP2016009604A0 (fr)
AU (1) AU2014396394A1 (fr)
BR (1) BR112016028674A2 (fr)
CA (1) CA2950250A1 (fr)
CL (1) CL2016003102A1 (fr)
EA (1) EA201692371A1 (fr)
HK (1) HK1231469A1 (fr)
IL (1) IL249118A0 (fr)
MA (1) MA39524A1 (fr)
MX (1) MX2016015350A (fr)
PH (1) PH12016502432A1 (fr)
SG (1) SG11201610149YA (fr)
WO (1) WO2015186137A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014396394A1 (en) * 2014-06-06 2016-12-08 Natco Pharma Limited 1H-1,8- naphthyridin-2ones as anti proliferative compounds
CN107663151B (zh) * 2016-07-28 2021-11-26 江苏豪森药业集团有限公司 甲磺酸氟马替尼的中间体合成方法
CN108473476B (zh) * 2016-10-13 2021-02-19 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的炔基杂环类化合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1973545T3 (pl) 2005-12-23 2013-05-31 Ariad Pharma Inc Bicykliczne Związki Heteroarylowe
KR20090018104A (ko) * 2006-05-08 2009-02-19 어리어드 파마슈티칼스, 인코포레이티드 아세틸렌계 헤테로아릴 화합물
CN101490053B (zh) * 2006-05-08 2013-09-11 阿里亚德医药股份有限公司 单环杂芳基化合物
US7790756B2 (en) 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
US9180127B2 (en) * 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
ES2636262T3 (es) 2010-01-29 2017-10-05 Hanmi Science Co., Ltd. Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora en las proteínas cinasas
AU2014396394A1 (en) * 2014-06-06 2016-12-08 Natco Pharma Limited 1H-1,8- naphthyridin-2ones as anti proliferative compounds

Also Published As

Publication number Publication date
BR112016028674A2 (pt) 2017-08-22
US20170349588A1 (en) 2017-12-07
US10047088B2 (en) 2018-08-14
US9765072B2 (en) 2017-09-19
PH12016502432A1 (en) 2017-03-06
SG11201610149YA (en) 2017-01-27
CL2016003102A1 (es) 2017-06-23
AP2016009604A0 (en) 2016-12-31
EA201692371A1 (ru) 2017-04-28
KR20170016921A (ko) 2017-02-14
JP2017516867A (ja) 2017-06-22
AU2014396394A1 (en) 2016-12-08
WO2015186137A1 (fr) 2015-12-10
EP3152205A1 (fr) 2017-04-12
US20170114057A1 (en) 2017-04-27
CN106573929A (zh) 2017-04-19
CA2950250A1 (fr) 2015-12-10
MX2016015350A (es) 2017-05-10
HK1231469A1 (zh) 2017-12-22
IL249118A0 (en) 2017-01-31

Similar Documents

Publication Publication Date Title
MA47079B1 (fr) Composés amino-triazolopyidines et leur utilisation pour traiter le cancer
PH12016500531B1 (en) Compound inhibiting activities of btk and/or jak3 kinases
BR112019007143A2 (pt) compostos de pirazolo[1,5-a]piridina substituídos como inibidores da ret cinase
BR112019007144B8 (pt) Compostos de pirazolo[1,5-a]piridina substituídos como inibidores da ret cinase
PH12018500087A1 (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
MA43169B1 (fr) Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma
MA39995B1 (fr) Composés destinés à traiter l'amyotrophie spinale
TN2017000119A1 (en) Indole carboxamides compounds useful as kinase inhibitors
EA201692095A1 (ru) Имидазо[4,5-c]хинолин-2-оновые соединения и их применение в лечении рака
MA38380A1 (fr) Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr)
MA41134A (fr) Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales
EA201791941A1 (ru) Бициклические кетосульфонамидные соединения
MA38391A1 (fr) Dérivés de pyridinyl et triazolone pyridinyl de fusion
GEP201706748B (en) Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
WO2016109217A3 (fr) Inhibiteurs de la btk
BR112019025049A2 (pt) Anéis 6- 5 fundidos como inibidores de c5a
TN2017000158A1 (en) Carbazole derivatives
EA202090052A1 (ru) Содержащие имидазол ингибиторы alk2 киназы
TN2016000188A1 (fr) Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs.
BR112019025230A2 (pt) Anéis 5-5 fundidos como inibidores de c5a
EA201790870A1 (ru) Трициклические атропоизомерные соединения
MA39524A1 (fr) 1h-1,8-naphthyridin-2 ones utilisées comme composés anti prolifératifs
PH12015502676A1 (en) 4-(5-(4-chlorophenyl)-2-(2-cyclopropylacetyl)-1,4-dimethyl-1h-pyrrol-3-yl)benzenesulfonamide as alpha 7 nachr modulator
MA39926B1 (fr) Dérivés de dihétérocycle liés à cycloalkyle
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines